Replacing Protein A Sorbents for the Large-Scale Manufacturing of Recombinant Antibodies: Hydrophobic Charge Induction Chromatography

by James Spencer, Egisto Boschetti, PhD, and Sylvio Bengio, PhD
Volume 2, Issue 3 (May/June 2003)

Monoclonal antibodies constitute a significant percentage of the protein-based therapeutic molecules currently in clinical trials. The broad applicability and proven commercial success for this class of molecules suggest a larger future market potential. The current biopharmaceutical manufacturing capacity is widely anticipated to be a rate-limiting factor in the growth of the biotech sector. Because antibody therapeutics represent such a large part of this market, and because the therapeutic dosages of antibodies tend to be greater than most biopharmaceuticals, there is an immediate need for novel antibody manufacturing approaches that deliver significantly greater productivity...

Citation:
Spencer J, Boschetti E, Bengio S. Replacing Protein A Sorbents for the Large-Scale Manufacturing of Recombinant Antibodies: Hydrophobic Charge Induction Chromatography. BioProcess J, 2003; 2(3): 67-72.